New topical treatment for mild to moderate plaque psoriasis
Part of Skin clinical trials.
This study tests a new topical medicine, GM-XAN003, for mild to moderate plaque psoriasis. It aims to see if it is safe and helps clear skin patches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years or older.
- You must have had chronic plaque psoriasis for at least 6 months, with mild to moderate symptoms.
- You must agree to stop other psoriasis treatments (like creams, light therapy, or immune pills) for at least 2 weeks before starting and during the study.
- You must have adequate liver, kidney, and blood counts (the study will check this with blood tests).
- If you can have children, you must agree to use reliable birth control during the study and for 4 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new ointment (XJH05) for people with mild-to-moderate plaque psoriasis. It aims to see if this treatment helps reduce symptoms and is safe for topical use.
This trial tests an oral medication called HS-10374 for people with mild to moderate plaque psoriasis who haven't gotten enough relief from topical treatments. The study will check if the drug is safe and effective at clearing psoriasis patches.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.